Invesco Ltd. Has $4.62 Million Holdings in Organogenesis $ORGO

Key Points

• Invesco Ltd. significantly increased its stake in Organogenesis by 779.7% in the first quarter, acquiring an additional 947,705 shares, bringing its total holdings to over 1 million shares valued at approximately $4.62 million.
• Organogenesis reported an EPS of ($0.09) for the latest quarter, missing analysts' expectations, and posted a revenue of $101.01 million, below the consensus estimate of $104.75 million.
• Analysts have mixed sentiments on the stock, with a few rating it as a "Buy" and a revised price target set at $9.00 by Cantor Fitzgerald, while the average target remains at $7.50.

Invesco Ltd. raised its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 779.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,069,252 shares of the company's stock after purchasing an additional 947,705 shares during the quarter. Invesco Ltd. owned 0.84% of Organogenesis worth $4,619,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Soleus Capital Management L.P. increased its holdings in shares of Organogenesis by 5.4% during the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock worth $39,952,000 after purchasing an additional 645,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after purchasing an additional 841,618 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after purchasing an additional 442,772 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Organogenesis by 45.3% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company's stock worth $2,884,000 after purchasing an additional 208,038 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Organogenesis by 2.9% during the 4th quarter. Northern Trust Corp now owns 616,089 shares of the company's stock worth $1,971,000 after purchasing an additional 17,196 shares during the period. Institutional investors own 49.57% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. BTIG Research reissued a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Cantor Fitzgerald upped their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $7.50.

Insider Buying and Selling

In other news, insider Lori Freedman purchased 142,379 shares of Organogenesis stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $2.91 per share, for a total transaction of $414,322.89. Following the completion of the transaction, the insider directly owned 837,437 shares in the company, valued at approximately $2,436,941.67. This represents a 20.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 33.00% of the stock is currently owned by company insiders.

Organogenesis Stock Up 1.2%

NASDAQ:ORGO traded up $0.06 on Wednesday, reaching $4.96. The stock had a trading volume of 1,556,499 shares, compared to its average volume of 613,956. The company has a market capitalization of $629.23 million, a P/E ratio of -35.43 and a beta of 1.75. Organogenesis has a 1-year low of $2.45 and a 1-year high of $6.71. The stock has a fifty day moving average price of $4.56 and a 200-day moving average price of $4.20.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The firm had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.